Chemical Data :

IUPAC: N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide

CAS: 1185887-21-1

ChemSpider: 30646774

Molecular Weight: 356.46 g/mol

Molecular Formula: C20H28N4O2


AB-CHMINACA is a synthetic cannabinoid of the indazole class. Like other indazole and indole synthetic cannabinoids, AB-CHMINACA is a potent and full agonist as the human cannabinoid receptor CB1 with a Ki value of 0.78 nM and at CB2 with a Ki value of 0.45 nM. It is 16 times more potent than THC, the primary psychoactive constituent of marijuana. Rats trained to respond to THC are unable to distinguish AB-CHMINACA from THC.

The indazole moiety forms the structural backbone of the molecule. The R1 nitrogen is bonded to a cyclohexyl group via a methyl bridge. At R3 in the indazole ring a valine amino acid is bonded. A carboxamid bridge links these.

The inclusion of the valine amino acid is in keeping with more recent trends in the indole and indazole cannabinoids where amino acids are used in place of adamantine or anphthyl moieties in previous versions.

AB-CHMINACA bears a close structural relation to the better known cannabinoid AB-FUBINACA. The 4-fluorophenyl group in AB-FUNINACA is replaced by a cyclohexyl to produce AB-CHMINACA.

AB-CHMINACA is linked to a number of deaths, seizures, delirium and psychotic episodes.

There are no studies in to the long term health implications of short term or long term use of AB-CHMINACA and other cannabinoids.

The physiological and toxicological profile of AB-CHIMINACA is not known.

AB-CHMINACA is not intended for animal or human consumption.

Subjective online reports suggest this is one of the most potent and strongest synthetic cannabinoids around.

It is reported as having sedating and “stoning” effects greater than AB-FUBINACA and very long lasting. It is speculated by some that the presence of the cyclohexylmethyl potentiates the molecule and reduces the rate of its metabolism in vivo. The quality of the experience was said to be more akin to an indica strain of marijuana producing a strong sedation and body high.

Users report that it is possible to have a very uncomfortable overdose with this substance owing to its high potency. During overdose the rush from the chemical is said to be scary. The user will feel a strain on their chest and tightness. Cognitively this is often accompanied by extreme dissociation and derealisation.  In fact it is possible to have a fatal overdose or one that leads to hospitalisation or seizure.

With this in mind people still keen to use need to be very aware of the appropriate dose. This is often in the low mg range for these potent synthetic cannabinoids. For AB-CHMINACA there have been reports of doses around 0.5 mg – 1 mg. Users must conduct their own research. This will vary according the the sensitivity, tolerance, body weight and metabolism of the individual. Such small doses cannot be measured on a conventional scale. It requires mg sensitive scales or even more accurately volumetric dosing.

The synthetic cannabinoids are known to be habit forming. Continual use may lead to psychological dependence over time. Tolerance may also build with repeated use. Individuals have found that after consistent use over a period of time withdrawal side effects and cravings will manifest when stopping.

Other names and synonyms for AB-Chminaca:

1185887-21-1 [RN]
1H-Indazole-3-carboxamide, N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)- [ACD/Index Name]
N-[(2S)-1-Amino-3-methyl-1-oxo-2-butanyl]-1-(cyclohexylmethyl)-1H-indazol-3-carboxamid [German] [ACD/IUPAC Name]
N-[(2S)-1-Amino-3-methyl-1-oxo-2-butanyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide [ACD/IUPAC Name]
N-[(2S)-1-Amino-3-méthyl-1-oxo-2-butanyl]-1-(cyclohexylméthyl)-1H-indazole-3-carboxamide [French] [ACD/IUPAC Name]